Policy – Page 2

CDC Vaccine Advisory Committee Meeting Postponed Following RFK Jr.’s Confirmation as HHS Secretary

2 months ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), CHARGE Syndrome, HHS, Immunization, Policy, public health medicine (field), Recommendation, Robert F. Kennedy, Vaccines

ACIP, CDC, vaccine recommendations, Robert F. Kennedy Jr., HHS, postponement, public health, immunization policy

Trump Imposes New Tariffs on Canada, Mexico, and China; Medical Industry Seeks Exemptions

3 months ago talkbio0Tagged Canada, China, fentanyl crisis, illegal immigration, medical technology exemptions, Mexico, National Security, Policy, TNFRSF19 gene, Trump tariffs

Trump tariffs, Canada, Mexico, China, medical technology exemptions, trade policy, national security, fentanyl crisis, illegal immigration

Trump 2.0: RFK Confirmation Hearings and Ongoing Clinical Trials Amidst Administrative Changes

3 months ago talkbio0Tagged Clinical Trials, Confirmation, Hearings, NIH Mouse, Partnership, Policy, RFK gene, Transplant Registry Unified Management Program

Trump 2.0, RFK Confirmation Hearings, Clinical Trials, NIH Grant Reviews, US-India Partnership, Second Term Policies

Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns

5 months ago talkbio0Tagged Acquisitions, Administration occupational activities, Biopharma, Independence, Inflation, mergers, Policy, Transplant Registry Unified Management Program, United States Food and Drug Administration, Vaccines

Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

5 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty

Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration

6 months ago talkbio0Tagged Administration occupational activities, Agriculture, Biopharma, Health care facility, Policy, RFK Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy

Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action

8 months ago talkbio0Tagged Contact Role - Federal Agency, Gegenhalten, Health care facility, Johnson & Johnson, Policy, Programs - Publication Format, Rebate Model

340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy

Unlocking Direct-to-Consumer (DTC) Adoption: Leveraging Telehealth Programs for Enhanced Healthcare Access” ###

11 months ago talkbio0Tagged Adoption, clinical networks, Consumer health, Consumption of goods, Direct-to-Consumer, DTC, Health care facility, perspectives, pharma leaders, Policy, Primary Health Care, Reimbursement models, Services, Telemedicine, virtual care platforms

Direct-to-Consumer (DTC) digital health, Telehealth adoption, Virtual care platforms, Clinical networks, Consumer health and pharma leaders, Telemedicine services, Healthcare consumption, Primary care, Reimbursement models, Policy perspectives

Record-Breaking 323 Medications in Active Shortage in US, ASHP Reports

1 year ago talkbio0Tagged Active shortages, Adderall, American Society of Health-System Pharmacists, Antineoplastic Agents, ASHP, Attention deficit hyperactivity disorder, Drug Enforcement Administration, Drug shortages, Drug supply chains, Generic sterile injectable medications, Policy, Recommendation, Record-high

Drug shortages, US, Record-high, American Society of Health-System Pharmacists (ASHP), 323 medications, Active shortages, Generic sterile injectable medications, Cancer chemotherapy drugs, ADHD medications, Adderall, Drug Enforcement Administration (DEA), Drug supply chains, Policy recommendations